Randomized,Open-Label,Comparative Safety and Effacy Study of Tipranavir Boosted with Low-dose Ritonavir (TPV/RTV) Versus Genotypically-defined Protease Inhibitor/Ritonavir (PI/RTV) in Multiple Antiretrovial Drug-Experienced Patients (Resist 1:)

Grants and Contracts Details

StatusFinished
Effective start/end date3/1/03 → 7/31/11

Funding

  • Boehringer-Ingelheim: $57,219.00